Valcyte Related Published Studies
Well-designed clinical trials related to Valcyte (Valganciclovir)
Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. [2009.05]
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. [2009]
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. [2008.07.01]
Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. [2008.01]
Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. [2006.06]
Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. [2006.04.01]
Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. [2005.06.15]
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. [2005]
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. [2004.05.01]
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. [2004.04]
A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. [2002.04.11]
Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. [2001.12.15]
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. [2000.10]
Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. [1999.08]
Well-designed clinical trials possibly related to Valcyte (Valganciclovir)
Antiviral agents for treatment of herpes simplex virus infection in neonates. [2009.07.08]
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. [2009.05]
Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. [2009.05]
An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. [2009.02]
Cytomegalovirus infection after liver transplantation: current concepts and challenges. [2008.08.21]
Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients. [2007.05]
Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. [2006.07.27]
A surveillance study of adenovirus infection in adult solid organ transplant recipients. [2005.10]
Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. [2005.09]
Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. [2005.05]
Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. [2004.12.27]
Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. [2004.04]
Other research related to Valcyte (Valganciclovir)
Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases. [2009.06]
Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. [2009.06]
[Prolonged treatment with valganciclovir in an infant with congenital cytomegalovirus infection] [2009.06]
A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. [2009.05]
Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil. [2009.04]
Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report. [2009.04]
Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. [2009.04]
Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. [2009.03]
Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. [2009.03]
Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. [2009.03]
Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. [2009.03]
Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. [2009.02]
Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. [2009.02]
Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. [2009.01]
Human herpesvirus 6 meningoradiculitis treated with intravenous immunoglobulin and valganciclovir. [2009.01]
Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. [2009]
[Valganciclovir for treatment of cytomegalovirus viremia in patients following allogeneic hematopoietic stem cell transplantation] [2008.12.16]
Randomized prospective study of the evolution of renal function depending on the anticalcineurin used. [2008.11]
Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. [2008.10]
Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. [2008.09.19]
Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. [2008.09]
Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. [2008.08]
Cytomegalovirus glomerulopathy in a kidney allograft with response to oral valganciclovir. [2008.07]
Cytomegalovirus prophylaxis with valganciclovir in cytomegalovirus-seropositive kidney-transplant patients. [2008.07]
Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. [2008.06]
Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. [2008.06]
High incidence of cytomegalovirus disease in D+/R- heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis. [2008.05]
Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. [2008.04]
Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. [2008.03.15]
Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. [2008.03.15]
Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. [2008.03]
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. [2008.02.15]
Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. [2008.02]
Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. [2008.01.01]
Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant. [2008.01]
[Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir] [2008]
Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: successful treatment with oral valganciclovir. [2008]
Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. [2007.12.01]
Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. [2007.12]
Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients. [2007.12]
Valganciclovir prevents CMV reactivation in patients receiving alemtuzumab based therapy. [2007.11.26]
Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal Transplantation. [2007.10.31]
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. [2007.09]
Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients. [2007.09]
Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients. [2007.07.19]
Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. [2007.06]
Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. [2007.06]
Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in chinese cardiac recipients. [2007.06]
Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants. [2007.05]
CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction. [2007.03]
Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. [2007.02.15]
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. [2007.02]
Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation. [2007.01]
Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients. [2006.12]
Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. [2006.12]
Successful treatment with oral valganciclovir in immunocompetent infant with gastrointestinal manifestations of cytomegalovirus infection. [2006.10]
Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. [2006.09.01]
Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. [2006.09]
Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. [2006.07.15]
Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. [2006.05]
Treatment of cytomegalovirus retinitis with oral valganciclovir in an acquired immunodeficiency syndrome patient unresponsive to combination antiretroviral therapy. [2006.04]
Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. [2006.04]
Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. [2006.01]
Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring. [2006.01]
[Evaluation of pharmacokinetics and safety of valganciclovir oral suspension treatment in pediatric kidney graft recipients--preliminary report] [2006]
Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. [2005.12.13]
Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. [2005.11]
A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. [2005.10.01]
[Cytomegalovirus viral load and antigenemia in the monitorization of prophylactic treatment with valganciclovir in renal transplant recipients] [2005.09]
Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infection. [2005.09]
Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation. [2005.07]
A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. [2005.06]
Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. [2005.04]
Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. [2005.03]
Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. [2005.01.15]
|
